Dupilumab treatment led to significant SCORAD score reductions, with 37% achieving a 75% reduction and 72% reaching mild disease status by week 16. Improvements were observed as early as week 2, with ...
NEW YORK CITY -- An oral drug that targets Th2 activity in atopic dermatitis reduced disease activity by as much as 50% after 6 weeks, results of a small placebo-controlled study showed. At 4 weeks of ...
This study developed an AI model that accurately detects body parts and eczema lesions and objectively assesses eczema severity (TIS score), demonstrating strong correlation with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results